Clinical Trial Detail

NCT ID NCT03241810
Title Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Merrimack Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant

Fulvestrant + Seribantumab

Age Groups: adult senior

Additional content available in CKB BOOST